X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload. The trial is expected to begin in Q1 2024.
Lead Product(s): ASP1012
Therapeutic Area: Oncology Product Name: ASP1012
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Lead Product(s): Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 15, 2022
Details:
Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VETTM platform, including VET-ROG1 expressing Roche proprietary therapeutic transgenes.
Lead Product(s): VET-ROG1
Therapeutic Area: Oncology Product Name: VET-ROG1
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 23, 2022
Details:
Under the terms of the agreement, Astellas will pay to KaliVir up to US$56 million in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the Second Product.
Lead Product(s): VET2-L2
Therapeutic Area: Oncology Product Name: VET2-L2
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $634.0 million Upfront Cash: $56.0 million
Deal Type: Collaboration December 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
